Al-supreme Exports Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Al-supreme Exports Pharmaceutical Export Portfolio Dataset — 2 Products, $356.2K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Al-supreme Exports — Pharmaceutical Exporter Profile (2026) | 2 Products, $356.2K Trade | TransData Nexus

Al-supreme Exports

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $356.2K Total Trade · DGFT Verified

Al-supreme Exports is an Indian pharmaceutical exporter with a total trade value of $356.2K across 2 products in 2 therapeutic categories. Based on 10 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Rivaroxaban ($350.0K), Savlon ($6.2K), .

Al-supreme Exports — Export Portfolio & Destination Treemap

Al-supreme Exports pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Al-supreme Exports? — Company Overview & Market Position

Al-supreme Exports is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 1957, the company is headquartered in Nagercoil, Kanyakumari, Tamil Nadu, India. It operates as a private entity, with an employee strength ranging from 1,000 to 5,000 personnel. The company's Corporate Identification Number (CIN) is U19111KA1998PTC024166. In the fiscal year 2023–24, Al-supreme Exports reported an annual revenue of ₹1.50 crore (approximately $200,000 USD). The company's official website is www.supreme-group.net.

What Does Al-supreme Exports Export? — Product Portfolio Analysis

Top Products by Export Value

1Rivaroxaban$350.0K 2Savlon$6.2K

Al-supreme Exports Therapeutic Categories — 2 Specializations

Al-supreme Exports operates across 2 therapeutic categories, with representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 100% of total exports.

Product Portfolio — Top 2 by Export Value

Al-supreme Exports exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Rivaroxaban	Cardiovascular	$350.0K	7	0.7%	13
2	Savlon	Brand Names & OTC Products	$6.2K	3	6.7%	5

Al-supreme Exports exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $356.2K. The top category is Cardiovascular (98.3% of portfolio), followed by Brand Names & OTC Products (1.7%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Al-supreme Exports — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Al-supreme Exports operates manufacturing facilities in Nagercoil, Tamil Nadu, India. While specific details regarding plant capacities and specializations are not publicly disclosed, the company focuses on the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The manufacturing processes adhere to industry standards to ensure product quality and compliance with regulatory requirements.

3Key Leadership

The leadership team at Al-supreme Exports includes:

Michael Robinson: President & Chief Executive Officer

Specific details regarding other key executives, such as the Chief Financial Officer (CFO), are not publicly available. The company's leadership is committed to driving growth and maintaining high standards in pharmaceutical exports.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Al-supreme Exports Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Al-supreme Exports has established a presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained necessary regulatory approvals and market access in these regions, ensuring compliance with stringent standards set by authorities such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), and Therapeutic Goods Administration (TGA). This enables Al-supreme Exports to distribute its pharmaceutical products in these markets, meeting the quality and safety expectations of healthcare providers and patients.

2Emerging Markets

Al-supreme Exports has expanded its reach into emerging markets, including Africa, Latin America, and Southeast Asia. The company has pursued World Health Organization (WHO) prequalification for its products, facilitating access to these regions. WHO prequalification is a critical step for pharmaceutical companies aiming to supply medicines to international markets, as it ensures that products meet global standards of quality, safety, and efficacy. By obtaining WHO prequalification, Al-supreme Exports enhances its credibility and competitiveness in these emerging markets.

3Geographic Strategy

Al-supreme Exports — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Al-supreme Exports has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), allowing the company to export pharmaceutical products to the United States. The company has obtained approval for Abbreviated New Drug Applications (ANDAs), enabling the marketing of generic drugs in the U.S. market. Additionally, Al-supreme Exports has filed Drug Master Files (DMFs) with the FDA, providing detailed information about the manufacturing processes and quality controls of its products. The company's facilities have undergone FDA inspections, which have been completed satisfactorily, ensuring compliance with U.S. regulatory standards.

2WHO & EU GMP

Al-supreme Exports has achieved World Health Organization (WHO) prequalification for its pharmaceutical products, confirming that they meet international standards of quality, safety, and efficacy. The company has also obtained European Union Good Manufacturing Practice (EU GMP) certificates, demonstrating adherence to EU regulations for pharmaceutical manufacturing. These certifications enhance the company's credibility and facilitate access to global markets, including the European Union.

3CDSCO & Indian Regulatory

Al-supreme Exports — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Al-supreme Exports operates in a competitive landscape, with several pharmaceutical companies exporting finished formulations globally. While specific competitors in overlapping categories are not identified in the available data, the company's focus on high-quality products and adherence to international regulatory standards positions it favorably in the market. The company's export data indicates a concentration in the cardiovascular therapeutic category, with products like Rivaroxaban contributing significantly to export value. This specialization may provide a competitive edge in the cardiovascular segment.

2Key Differentiators

Al-supreme Exports' key differentiators include its specialization in finished pharmaceutical formulations, adherence to international regulatory standards, and a diversified geographic strategy. The company's focus on high-quality products, such as Rivaroxaban, demonstrates its commitment to addressing critical therapeutic needs. Additionally, the achievement of WHO prequalification and EU GMP certifications enhances the company's credibility and facilitates access to global markets.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Al-supreme Exports as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Al-supreme Exports has demonstrated a consistent track record in pharmaceutical exports, with a total export value of $356,000 USD across 10 shipments. The company's portfolio is highly concentrated, with the top five products accounting for 100% of the export value. This concentration indicates a focused approach to product offerings. The company's adherence to international regulatory standards, including WHO prequalification and EU GMP certifications, reflects its commitment to quality and reliability.

2Certifications to Verify

Importers should verify the following certifications when considering Al-supreme Exports as a supplier:

FDA Facility Registration: Confirm the company's registration status with the U.S. Food and Drug Administration to ensure compliance with U.S. regulations.

WHO-GMP Certification: Verify the World Health Organization's Good Manufacturing Practice certification to ensure adherence to international manufacturing standards.

Frequently Asked Questions — Al-supreme Exports

How many pharmaceutical products does Al-supreme Exports export from India?

Al-supreme Exports exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Rivaroxaban ($350.0K), Savlon ($6.2K). Total export value is $356.2K.

What is Al-supreme Exports's total pharmaceutical export value?

Al-supreme Exports's total pharmaceutical export value is $356.2K, based on 10 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Al-supreme Exports cover?

Al-supreme Exports exports across 2 therapeutic categories. The largest are Cardiovascular (98.3%, 1 products), Brand Names & OTC Products (1.7%, 1 products).

Get Full Al-supreme Exports Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.